TY - JOUR
T1 - STAP-2 Is a Novel Positive Regulator of TCR-Proximal Signals
AU - Saitoh, Kodai
AU - Kashiwakura, Jun Ichi
AU - Kagohashi, Kota
AU - Sasaki, Yuto
AU - Kawahara, Shoya
AU - Sekine, Yuichi
AU - Kitai, Yuichi
AU - Muromoto, Ryuta
AU - Ichii, Michiko
AU - Nakatsukasa, Hiroko
AU - Yoshimura, Akihiko
AU - Oritani, Kenji
AU - Matsuda, Tadashi
N1 - Funding Information:
We thank Pharma Science Open Unit (PSOU), Global Facility Center (GFC), Hokkaido University, funded by MEXT under the Support Program for Implementation of New Equipment Sharing System. We also thank Katie Oakley, PhD, from Edanz Group (www.edanzediting.com/ac) for editing a draft of the manuscript.
Funding Information:
This work was supported by Japan Society for the Promotion of Science KAKENHI Grants 19H03364 (T.M.), 16K09872 (K.O.), 19K08815 (M.I.), 17H06175 (A.Y.), and 18J10479 (K.S.) and by Japan Agency for Medical Research and Development CREST JP 20gm1110009 (A.Y.).
Publisher Copyright:
© 2022 by TheAmericanAssociation of Immunologists, Inc.
PY - 2022/7/1
Y1 - 2022/7/1
N2 - TCR ligation with an Ag presented on MHC molecules promotes T cell activation, leading to the selection, differentiation, and proliferation of T cells and cytokine production. These immunological events are optimally arranged to provide appropriate responses against a variety of pathogens. We here propose signal-transducing adaptor protein-2 (STAP-2) as a new positive regulator of TCR signaling. STAP-2-deficient T cells showed reduced, whereas STAP-2-overexpressing T cells showed enhanced, TCR-mediated signaling and downstream IL-2 production. For the mechanisms, STAP-2 associated with TCR-proximal CD3f immunoreceptor tyrosine activation motifs and phosphorylated LCK, resulting in enhancement of their binding after TCR stimulation. In parallel, STAP-2 expression is required for full activation of downstream TCR signaling. Importantly, STAP-2-deficient mice exhibited slight phenotypes of CD4+ T-cell-mediated inflammatory diseases, such as experimental autoimmune encephalomyelitis, whereas STAP-2-overexpressing transgenic mice showed severe phenotypes of these diseases. Together, STAP-2 is an adaptor protein to enhance TCR signaling; therefore, manipulating STAP-2 will have an ability to improve the treatment of patients with autoimmune diseases as well as the chimeric Ag receptor T cell therapy.
AB - TCR ligation with an Ag presented on MHC molecules promotes T cell activation, leading to the selection, differentiation, and proliferation of T cells and cytokine production. These immunological events are optimally arranged to provide appropriate responses against a variety of pathogens. We here propose signal-transducing adaptor protein-2 (STAP-2) as a new positive regulator of TCR signaling. STAP-2-deficient T cells showed reduced, whereas STAP-2-overexpressing T cells showed enhanced, TCR-mediated signaling and downstream IL-2 production. For the mechanisms, STAP-2 associated with TCR-proximal CD3f immunoreceptor tyrosine activation motifs and phosphorylated LCK, resulting in enhancement of their binding after TCR stimulation. In parallel, STAP-2 expression is required for full activation of downstream TCR signaling. Importantly, STAP-2-deficient mice exhibited slight phenotypes of CD4+ T-cell-mediated inflammatory diseases, such as experimental autoimmune encephalomyelitis, whereas STAP-2-overexpressing transgenic mice showed severe phenotypes of these diseases. Together, STAP-2 is an adaptor protein to enhance TCR signaling; therefore, manipulating STAP-2 will have an ability to improve the treatment of patients with autoimmune diseases as well as the chimeric Ag receptor T cell therapy.
UR - http://www.scopus.com/inward/record.url?scp=85133215076&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133215076&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.2101014
DO - 10.4049/jimmunol.2101014
M3 - Article
C2 - 35725273
AN - SCOPUS:85133215076
SN - 0022-1767
VL - 209
SP - 57
EP - 68
JO - Journal of Immunology
JF - Journal of Immunology
IS - 1
ER -